Consult our clinical studies and their summaries to verify the effectiveness of RestoreX™
Study No. 1A | Study No. 2A | Study No. 3A | Study No. 4A | Study No. 5A | Study No. 6A |
M.J. Ziegelmann & al. : Outcomes of a Novel Penile Traction Device in Men with Peyronie's Disease: A Randomized, Single-Blind, Controlled Trial /AUA - The Journal of Urology – September 2019, Volume 202, Page: 599-610
Prospective, randomized clinical trial of traction therapy
penile with RestoreX™ in men with Peyronie's disease: initial phase results (3 months).
J. Joseph & al. : Outcomes of RestoreX™ Penile Traction Therapy in Men with Peyronie's Disease: Results from Open Label and Follow-up Phases / The Journal of Sexual Medicine – 2020; 17:2462-2471
Prospective and randomized clinical study of penile traction therapy with RestoreX™ in men with Peyronie's disease: results of the follow-up phase (6 and 9 months) after the initial phase (3 months).
K. Wymer & al. : Comparative Cost-effectiveness of Surgery, Collagenase Clostridium Histolyticum, and Penile Traction Therapy in Men with Peyronie's Disease in an Era of Effective Clinical Treatment /The Journal of Sexual Medicine - 2019;16:1421e1432
Cost-effectiveness comparison in the United States of 3 therapies for Peyronie's disease : RestoreX (traction therapy) vs Clostridium Histolyticum Collagenase vs Surgery.
M.J. Ziegelmann & al. : Clinical Experience with Penile Traction Therapy Among Men Undergoing Collagenase Clostridium histolyticum for Peyronie's Disease /AUA - The Journal of Urology – January 2017104: 108
Evaluation of the treatment of Peyronie's disease with Clostridium Histolyticum Collagenase (CCH) combined with a traction therapy device (Andropenis™).
Mr. Alom & al. : Efficacy of Combined Collagenase Clostridium histolyticum and RestoreX™ Penile Traction Therapy in Men with Peyronie's Disease /Tea Journal of Sexual Medicine - 2019;16:891e900
Evaluation of the safety and efficacy of RestoreX™ combined with Clostridium Histolyticum Collagenase (CCH) compared to CCH alone and to CCH combined with other traction therapy devices (AndroPenis™, X4 Labs Penis Extender™ and PeniMaster™).
B. Green & al.: Comparison of Collagenase Clostridium histolyticum to Surgery for the Management of Peyronie's Disease: A Randomized Trial The Journal of Urology 210(5):p 791-802, November 2023.
A prospective, randomized clinical trial comparing Peyronie's disease therapy between group 1: Clostridium Histolyticum Collagenase + RestoreX™ + Sildenafil (CCH group) versus another therapy Surgery + RestoreX™ + Sildenafil (surgical group).
